Aptevo Therapeutics Inc (APVO) Stock Price, Quote & News

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 838 0500

Fax: 206 838 0503

Website: aptevotherapeutics.com

Address:

2401 4th Avenue, Suite 1050, Seattle, United States

DonZulu Jul. 17 at 7:03 PM

$APVO in compliance and when you least expect this will rocket to the moon when someone buys there meds ill be here ready

0 · Reply

JonBarron299 Jul. 17 at 3:14 AM

$APVO Avoiding overreaction to volatility

0 · Reply

Joan2109 Jul. 16 at 2:25 PM

$NUWE same scam like, $APVO and $INMB

0 · Reply

Voric Jul. 15 at 10:26 PM

$APVO i don't understand this silence

1 · Reply

David_M_ Jul. 15 at 1:11 PM

$APVO

0 · Reply

Narik Jul. 14 at 6:21 PM

$APVO i already got mail for another R/S...

2 · Reply

MicrocapCowboy Jul. 14 at 3:11 PM

$APVO Big Pharma buys clinical research...they want companies with pipelines. Two solid drugs in the oncology space is like untapped oil. To the guy who suggested I don't know what I'm talking about asking about market data, timelines, and suggested 12 more dilutions....do you not know how this works? This company isn't working toward profitability, they are working toward acquisition. I'm sticking with a 100-1000X multiple from the current price in the next 12 months. Laugh at me all you want...don't care.

0 · Reply

DonZulu Jul. 9 at 3:35 PM

$APVO moving up in channell

1 · Reply

dontfollowme22 Jul. 9 at 3:26 PM

$APVO company is making a lot of clinical studies and trials for curing leukemias and other malignancy diseases with excellent results and big hope to cure these illnesses in near future..

1 · Reply

dontfollowme22 Jul. 9 at 3:11 PM

$APVO our primary target is around 500 $ 💰💰 it’s only 3 $ now 🥰 I promise ✈️

1 · Reply

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 8:55 AM EDT - 27 days ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:01 AM EDT - 27 days ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Jun 18, 2025, 1:34 PM EDT - 4 weeks ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 11:37 AM EDT - 4 weeks ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 10:52 AM EDT - 4 weeks ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 8:01 AM EDT - 4 weeks ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 13, 2025, 8:05 AM EDT - 4 weeks ago

Aptevo Participating in the BIO International Convention

May 22, 2025, 8:05 AM EDT - 2 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 15, 2025, 8:05 AM EDT - 2 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 8, 2025, 8:45 AM EDT - 2 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Apr 22, 2025, 4:05 PM EDT - 3 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 3 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 3 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 3 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 20, 2025, 8:35 AM EDT - 4 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 18, 2025, 8:05 AM EDT - 4 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 6, 2025, 8:00 AM EST - 4 months ago

Aptevo to Participate in March Conferences

Feb 15, 2025, 6:59 PM EST - 5 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 14, 2025, 8:05 AM EST - 5 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Jan 15, 2025, 8:00 AM EST - 6 months ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Dec 12, 2024, 12:50 PM EST - 7 months ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 9:00 AM EST - 7 months ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 4, 2024, 8:35 AM EST - 8 months ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Nov 29, 2024, 9:55 AM EST - 8 months ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 26, 2024, 8:35 AM EST - 8 months ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 22, 2024, 8:35 AM EST - 8 months ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 20, 2024, 8:35 AM EST - 8 months ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 11, 2024, 8:15 AM EST - 8 months ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 7, 2024, 8:05 AM EST - 9 months ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Sep 18, 2024, 4:05 PM EDT - 10 months ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 10 months ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

May 14, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

May 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Apr 10, 2024, 9:00 AM EDT - 1 year ago

Aptevo Therapeutics Provides Pipeline Update

Mar 18, 2024, 6:00 AM EDT - 1 year ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Mar 5, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Mar 4, 2024, 9:00 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 14, 2023, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Nov 1, 2023, 7:45 AM EDT - 1 year ago

Aptevo to Present at Bio-Europe Conference

Aug 10, 2023, 8:05 AM EDT - 2 years ago

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

Aug 4, 2023, 6:40 PM EDT - 2 years ago

Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

Aug 1, 2023, 10:15 PM EDT - 2 years ago

Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering

Jul 18, 2023, 8:05 AM EDT - 2 years ago

Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML

DonZulu Jul. 17 at 7:03 PM

$APVO in compliance and when you least expect this will rocket to the moon when someone buys there meds ill be here ready

0 · Reply

JonBarron299 Jul. 17 at 3:14 AM

$APVO Avoiding overreaction to volatility

0 · Reply

Joan2109 Jul. 16 at 2:25 PM

$NUWE same scam like, $APVO and $INMB

0 · Reply

Voric Jul. 15 at 10:26 PM

$APVO i don't understand this silence

1 · Reply

David_M_ Jul. 15 at 1:11 PM

$APVO

0 · Reply

Narik Jul. 14 at 6:21 PM

$APVO i already got mail for another R/S...

2 · Reply

MicrocapCowboy Jul. 14 at 3:11 PM

0 · Reply

DonZulu Jul. 9 at 3:35 PM

$APVO moving up in channell

1 · Reply

dontfollowme22 Jul. 9 at 3:26 PM

$APVO company is making a lot of clinical studies and trials for curing leukemias and other malignancy diseases with excellent results and big hope to cure these illnesses in near future..

1 · Reply

dontfollowme22 Jul. 9 at 3:11 PM

$APVO our primary target is around 500 $ 💰💰 it’s only 3 $ now 🥰 I promise ✈️

1 · Reply

dontfollowme22 Jul. 9 at 3:08 PM

$APVO we still at the bottom, it’s your chance guys for big profits 🏦💰💰

0 · Reply

dontfollowme22 Jul. 9 at 3:06 PM

$APVO join the flight to space stars ⭐️ soooon guys ✈️

0 · Reply

MicrocapCowboy Jul. 9 at 2:30 PM

$APVO I know some may read this and just call me a hopeless pumper, but I couldn't care less. I don't think this will do anything of note for a few months...could even fade below $2, but as soon as their primary therapeutic is advanced in trials to the next phase, I believe we could see a number well beyond $420...with the current float, could even be 4 figures. A drug that send cancer into remission is worth billions...billions!....keep that in mind. This has nothing to do with company fundamentals...it's all about that intrinsic valuation.

1 · Reply

dontfollowme22 Jul. 9 at 2:17 PM

$APVO small market cap, stock price was recently so high, it will not stay here long , 1 year target is 420$ ✈️✈️ soon will fly

0 · Reply

dontfollowme22 Jul. 9 at 2:13 PM

$APVO is warming up guys ✈️ if it pumps you will not catch it easily ✈️✈️

0 · Reply

DonZulu Jul. 9 at 2:07 PM

$APVO 10$

0 · Reply

BellR Jul. 9 at 1:46 PM

$APVO

1 · Reply

macstock Jul. 9 at 1:59 AM

$APVO stocks down 87% in the last 90 days and one dead fish flop of 6-7% and pumpers coming out of the woodwork like their $20 investment is about to light it up 🤣

1 · Reply

David_M_ Jul. 8 at 9:20 PM

$APVO may be on its way up sympathy with RNAZ

0 · Reply

StockFlips Jul. 8 at 5:27 PM

$APVO looking coiled up 🪽

0 · Reply

Newguy21 Jul. 8 at 5:12 PM

$APVO she going up, have to put them rockets lol

0 · Reply

DonZulu Jul. 8 at 2:43 PM

$APVO watching for next few weeks for a move

0 · Reply

Market Cap	2.21M
Revenue (ttm)	0.00
Net Income (ttm)	-24.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	99,263
Avg Vol	2,854,446
Day's Range	N/A - N/A
Shares Out	756,000.00
Stochastic %K	50%
Beta	5.58
Analysts	Strong Buy
Price Target	$420.00